Imugene doses first patient in Phase 1 onCARlytics IV infusion combination trial

Proactive - Interviews for investors

Imugene Ltd (ASX:IMU OTCMKTS:IUGNF) CEO Leslie Chong sits down with Proactive’s Jonathan Jackson after the company dosed the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics trial. The patient, diagnosed with cholangiocarcinoma, received treatment at City of Hope in California. Imugene’s OASIS trial is the first to combine a CD19-expressing oncolytic virus with a CD19-targeting drug. Chong stated that the enrolment of the first IV combination patient advanced the OASIS trial, which integrated their CD19 oncolytic virus with the CD19 bispecific drug, blinatumomab (Blincyto®), in patients with advanced solid cancers. The Phase 1 trial aims to evaluate the safety and efficacy of onCARlytics (CF33-CD19) administered via intratumoural (IT) injection or IV infusion. The treatment may be given alone or with blinatumomab. Currently, the trial is being conducted at City of Hope, University of Cincinnati, and MD Anderson Cancer Center, with plans to expand to 10 sites to recruit 40-45 patients with advanced solid cancers. The primary objective is to assess the safety and efficacy of onCARlytics via IT or IV routes, as monotherapy or in combination with blinatumomab. The trial began dosing its first IV monotherapy patient with bile tract cancer in February, with early combination data expected by Q4 2024. CD19 is a significant target for blood cancers, representing about 10% of all cancers. However, solid cancers lack a common surface target. onCARlytics aims to convert solid tumours into CD19-expressing tumours, making them treatable with CD19-targeting therapies. If successful, this approach could extend CD19 therapies to 90% of the cancer market, valued at US$532 billion by 2032. #ProactiveInvestors #Imugene #ASX #CancerTreatment #onCARlytics #CD19Therapy #Cholangiocarcinoma #OASISTrial #ClinicalTrials #Biotech #CancerResearch #Immunotherapy #Oncology #MedicalResearch #HealthNews #CityOfHope #Blincyto #Blinatumomab #SolidTumours #CancerCare #MedicalInnovation #USHealthcare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews